I would like to take it down to even a deeper level with one statement that was made by Mr. Burt, and that is, ”With the debate on endocrine-disrupting chemicals, we believe the science should continue to be developed by the risk assessors and endocrine disrupters continue to be considered in assessments wherever appropriate. There is no need to take special consideration of endocrine disruption into CEPA. The potential bioactivity”, etc.
What I would question you on this is, where there are vulnerable populations and marginalized communities, and such exposures during critical windows of vulnerability in assessments of cumulative exposures to substance and classes of substances, would you not say we need to take a more proactive approach at looking at those windows of opportunity and minimizing the toxic impacts they could have?